The effect of growth hormone (GH) on binding of epidermal growth factor (EGF) to liver membrane preparations was investigated in hypophysectomized mice and partially GH-deficient, genetic mutant "little" (lit/lit) mice. The EGF binding of normal male mice and testosterone-treated females was higher than in normal females. Due to diminished receptor concentration, hepatic EGF binding was decreased in male and female lit/lit mice to a level that was unaffected by gender or androgen treatment. GH replacement therapy by intermittent injections and continuous infusion restored the EGF binding of hypophysectomized mice to normal male and female levels, respectively, suggesting a role for the more pulsatile GH secretion in normal males. In lit/lit mice, however, both continuous and intermittent GH resulted in EGF binding levels comparable to those in normal females. In normal males continuous GH suppressed EGF binding. In conclusion, endogenous GH secretion induces EGF receptors in mice and this effect may be modulated by sex differences in GH secretion.
Introduction
Epidermal growth factor (EGF)' is a polypeptide originally isolated from the mouse submaxillary gland (1) . Subsequent studies have shown that EGF exerts a potent mitogenic action, but also modulates several other biological functions that are initiated by binding of EGF to a membrane-associated protein receptor (2, 3) . The results of recent studies indicate that the concentration of EGF receptors markedly affects growth properties at least in tumor cells (4, 5) . Thus, knowledge concerning the regulation of EGF receptors is essential for understanding the effects of EGF. There is, however, limited information about the possible role of EGF in physiological processes during adult life and about possible interactions between EGF and hormones involved in promoting growth. Growth hormone (GH), the major stimulator of postnatal growth, acts at least in part by stimulating production of insulin-like growth factor-I (IGF-I), which may function in a paracrine and autocrine as well as endocrine manner (6) (7) (8) . At present there is little information about GH interaction with other locally produced growth factors such as EGF.
Measurement of GH in repeated blood samples from cannulated undisturbed rats has convincingly demonstrated that, although mean plasma GH levels are similar in males and females, the GH secretory pattern is sex differentiated. Male rats, as well as androgen-treated females, display large GH pulses at 3-3.3-h intervals interrupted by low baseline secretion while normal females have smaller and more frequent pulses and higher baseline levels, i.e., more continuous GH secretion (9-1 1). Although comparable cannulation studies in mice are unavailable, measurement of plasma GH levels in single blood samples from large groups of animals are consistent with a more continuous and less variable GH secretion in females, i.e., sex-related differences similar to those in rats (12) . A pulsatile plasma GH pattern has been shown to be more effective than a continuous one in promoting body growth (10, 13, 14) , and the GH secretory pattern has also been implicated in the regulation of several sex-differentiated hepatic functions (10, 15) .
It has recently been reported that hepatic EGF receptor concentrations in male rodents can be increased by testosterone (16, 17) , raising the possibility that androgen-induced changes in the pattern of GH secretion exert a mediating role. In the present study we investigated the effect of GH on hepatic EGF binding in two models of isolated GH deficiency. Homozygous "little" (18) mice carry a recessive single gene mutation, designated lit, that affects the receptor for GH-releasing factor (19) . Although the lit/lit mouse, unlike other GH-deficient dwarf mouse strains and hypophysectomized animals, does not exhibit other pituitary hormone deficiencies (20, 21) , it is at present uncertain that the mutation affects only GH secretion. Therefore, studies were also performed in hypophysectomized mice given thyroxine, glucocorticoids, and testosterone as replacement therapy. To elucidate the possible role of the plasma GH pattern in determining the sex differentiation of hepatic EGF receptors, the effects of continuous and intermittent GH treatment were compared.
Human (BV-NPA-1 3) and bovine (NIH-GH-B 18) GH were provided through the National Hormone and Pituitary Program (Baltimore, MD). Continuous infusions of these hormones were accomplished using osmotic minipumps (model 2001, Alza Corp., Palo Alto, CA) implanted subcutaneously under ether anesthesia on the backs of the animals. The filling volume of these pumps is 225 ul and the pumping rate at 370C is 1 Ml/h. Osmotic minipumps filled with vehicle only were implanted in some of the control animals without any effect on EGF binding as compared with untreated animals. Human GH (I mg/kg per d) was given intermittently as subcutaneous injections at 12-h intervals at 800 and 2,000 h. The last injection was given 12 h before the animals were killed. Cortisone acetate (500,Mg/kg per d) and L-thyroxine (10,Mg/kg per d) were given to hypophysectomized mice in daily subcutaneous injections at 800 h. The hormone treatment continued for 5-7 d.
Female mice and hypophysectomized male mice were injected subcutaneously with testosterone enanthate (15 mg/kg) in 0.2 ml sesame oil 10 and 7 d, respectively, before measurement of hepatic EGF binding. Controls received vehicle only.
Hepatic membrane preparation. Immediately after decapitation of the animals, liver membranes were prepared by a modification of previously described methods (22, 23) . In brief, liver parenchymal tissue (usually 1 g) kept in ice-cold buffer (250 mM sucrose, 25 mM Tris-HCI, pH 7.4) was dissected free of connective tissue and larger vessels, finely minced, and washed. The tissue was then diluted to 5 vol of buffer and homogenized with a polytron (Brinkmann Instruments, Inc., Westbury, NY) at setting 7 for 90 s. The crude homogenate was filtered through two layers of cheesecloth and centrifuged at 600 g for 10 min. The supernatant containing the membrane fraction was then centrifuged at 10,000 g. The resulting supernatant was adjusted to 0.1 M NaCl and 0.2 mM MgSO4 and recentrifuged at 48,000 g for 40 min. The pellet was washed by resuspension in 50 mM Tris-HCI (pH 7.6) and centrifuged at 48,000 g for 30 min. All procedures were performed at 4°C. The pellet was then diluted in 50 mM Tris-HCl and stored in aliquots at -20°C. The protein content of the membranes was determined (24) using BSA as standard.
Receptor assay. EGF was prepared from male mouse submaxillary glands by the method of Savage et al. (25) . Radioiodination of EGF was performed using chloramine-T. The Fig. 1 . Maximal specific binding was reached after -30-45 min and then remained relatively constant, as previously reported (23, 27) . In subsequent studies incubation was always performed for 60 min at room temperature. In separate experiments the possible degradation of iodinated EGF during these conditions was investigated. After a standard assay incubation, the membranes were centrifuged and the supernatant was aspirated. More than 90% of the tracer in the supernatant could be precipitated by 10%/1 TCA. Moreover, the binding of tracer to fresh liver membranes was reduced by < 10% after preincubation at standard assay conditions, in line with the results of a previous study in which a slightly different protocol was used (26) . Data analysis. EGF receptor concentrations and binding dissociation constants were calculated according to the method of Scatchard (28), using data obtained from displacement experiments in which varying concentrations (0-66 nM) of unlabeled EGF were added to 0.3 nM of labeled EGF. The total concentration of bound EGF (labeled and unlabeled) was calculated assuming a similar relative specific binding of unlabeled and labeled EGF. The ratio of bound/free EGF was then plotted as a function of bound EGF, and the slope and the intercept with the x-axis were calculated by standard linear regression. Comparisons were made by t test, or, when more than two groups were compared, by one way analysis of variance followed by Student-Newman-Keul's multiple range test among different groups (29) . Data are presented as mean±SE. P values < 0.05 were considered significant.
Results
The results of preliminary studies indicated that the specific binding of EGF to hepatic membranes from GH deficient lit/lit male mice (3.9±1.3% total added radioactivity; n = 3) was markedly lower than to membranes of heterozygous +/lit male mice (24.0±2.8%; n = 3, P < 0.001). A fixed concentration of labeled EGF and varying concentrations of unlabeled EGF were incubated with +/lit and lit/lit liver membranes. The total specific EGF binding as a function of total concentration of added peptide is shown in Fig. 2 (Fig. 4) . In contrast, testosterone had no effect on EGF binding in lit/lit female mice. EGF binding was significantly lower in vehicle-treated lit/lit female mice as compared with vehicle-treated +/lit females, confirming the results in Fig. 3 . The effects ofcontinuous and intermittent (two subcutaneous injections per day) treatment with human GH on hepatic EGF binding were compared in male and female lit/lit mice. As shown in Fig. 5 , there was no difference between the effects of these two treatment protocols in either males or females. Both continuous and intermittent GH treatment restored EGF binding to a level comparable to that in +/lit female mice (Fig.  5, bottom) , but significantly lower than that in +/lit male mice (Fig. 5, top) .
The effects of continuous subcutaneous infusions of human and bovine GH were compared in a separate experiment. Specific hepatic EGF binding in lit/lit male mice treated with human (13.2+1 .5%; n = 5) and bovine ( 11.0±2.3%; In the present study hepatic EGF binding was significantly greater in normal male than female mice, confirming previous reports (16, 17) . Our data are also consistent with the hypothesis that the sex difference in hepatic EGF binding is related to the pattern of GH secretion. In addition to the marked decrease in EGF binding in both male and female lit/lit mice, the levels did not differ between the sexes, even though the secretion of other pituitary-dependent hormones, including sex ste- (20, 21 There is considerable evidence for androgen-dependent sex differentiation ofGH secretion in the rat (10, 11) and probably also the mouse (12) . GH secretion in normal males and androgen-treated females is characterized by episodic pulses every 3.3 h, whereas untreated females exhibit a more continuous pattern of GH secretion. The assumption that the plasma GH pattern is a determinant of hepatic EGF binding is supported by the present findings that intermittent administration of GH in a physiological replacement dose (13) ( 19, 20) , it is possible that the lit mutation also directly affects genes related to GH sensitivity. Alternatively, the continuous presence of low but measurable levels of endogenous GH in lit/lit mice plasma (30) may inhibit the masculinizing effect of intermittent GH. Continuous infusion of GH to normal male rodents suppresses EGF binding (present results) and feminizes various other functions (34, 35) . A continuous presence of GH in plasma of lit/lit mice could also explain why the female pattern of hepatic steroid metabolizing enzymes is not eliminated in female lit/lit mice (34) as in hypophysectomized female rats (32, 35) .
A common mechanism of hormonal interaction involves regulation of receptor binding capacity. The present results demonstrate that GH induces EGF receptors, though the precise physiological significance of this finding remains unknown. While a growth-related process appears likely, few sustained growth-related effects have been observed after EGF treatment of adult animals. However, in addition to its other effects on the liver, EGF enhances hepatic DNA synthesis in adult rats and mice (2, 36) , and there is recent evidence that the concentration of EGF receptors as well as of the ligand may influence cell proliferation under selected circumstances (4, 5) .
It is well established that GH interacts with a growth factor other than EGF (i.e., IGF-I), and that GH-stimulated synthesis of IGF-I in various tissues mediates, at least in part, the stimulatory effect of GH on body growth (6) (7) (8) . Although IGF-I and EGF interact under certain conditions in stimulating cell proliferation in vitro (37, 38), it remains unclear whether these growth factors interact in vivo, particularly in the liver, where there are relatively few IGF-I receptors in the adult rat (39). It is also currently unknown whether GH induces EGF receptors in tissues other than the liver.
Despite the above-mentioned unresolved questions, the present results raise the possibility that stimulation of EGF receptor levels and perhaps EGF sensitivity is of importance for the growth-promoting effect of GH. Thyroid hormone, which exerts an anabolic action on the liver of adult rodents (40) , also induces hepatic EGF receptors (27) . In addition, thyroid-stimulating hormone and estradiol increase EGF binding in the thyroid and the uterus, respectively, where these two hormones also stimulate cell proliferation (41, 42) . Therefore, enhanced EGF binding may constitute a common step in a cellular growth pathway that can be initiated by different stimuli.
